Auvelity europe approval status?

Is Auvelity approved in Europe yet?

Auvelity (dextromethorphan/bupropion) has been approved in Europe, including for adults with major depressive disorder (MDD) in line with the approved indications on European regulatory materials. [1]

Which European country first approved it, and what’s the current rollout?

European approvals can vary by country and timing. To track the latest status by specific country (and changes such as label updates or further indications), check the European Medicines Agency (EMA) and national medicines regulators for your target country. [1]

Who approved it in Europe, and under what process?

In Europe, medicines like Auvelity are typically assessed by EMA and then authorized for use across EU/EEA/other participating markets, with the exact “approved status” visible through EMA authorization pages and documents. [1]

Where to verify the most current status (EMA documents, dates, and label)

For the most up-to-date approval status and official documents, use EMA’s product information and authorization records. [1]

Patent/exclusivity angle (if you’re tracking market access timing)

If you’re looking at when Auvelity’s market exclusivity may change across Europe (relevant for generic or follow-on development), DrugPatentWatch.com can help map patent and exclusivity risks by product and geography. [2]

Sources:
[1] https://www.ema.europa.eu/en/medicines
[2] https://www.drugpatentwatch.com/